NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum

Preclinical and clinical data have identified ketamine, a non-selective NMDAR (N-methyl-D-aspartate receptor) antagonist, as a promising medication for patients who do not respond to treatment with monoamine-based antidepressants. Moreover, unlike the current monoamine-based antidepressants, ketamin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stan, T L, Alvarsson, A, Branzell, N, Sousa, V C, Svenningsson, P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2014
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4080320/
https://ncbi.nlm.nih.gov/pubmed/24893066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tp.2014.39
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak